Zoltan Szallasi
Overview
Explore the profile of Zoltan Szallasi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
169
Citations
18670
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
P Shanmugam S, Zhou Y, Stelter I, Hanlon T, Bekele R, Bellmunt J, et al.
Bladder Cancer
. 2025 Mar;
11(1):23523735251317865.
PMID: 40034244
Background: Enfortumab vedotin (EV) and Sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) with demonstrated activity in advanced bladder cancer. A subset of bladder tumors harbors a DNA repair deficiency in...
2.
Kilim O, Olar A, Biricz A, Madaras L, Pollner P, Szallasi Z, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):27.
PMID: 39863682
Patients with High-Grade Serous Ovarian Cancer (HGSOC) exhibit varied responses to treatment, with 20-30% showing de novo resistance to platinum-based chemotherapy. While hematoxylin-eosin (H&E)-stained pathological slides are used for routine...
3.
Biswas D, Liu Y, Herrero J, Wu Y, Moore D, Karasaki T, et al.
Nat Cancer
. 2025 Jan;
6(1):86-101.
PMID: 39789179
Human tumors are diverse in their natural history and response to treatment, which in part results from genetic and transcriptomic heterogeneity. In clinical practice, single-site needle biopsies are used to...
4.
Stormoen D, Lehn S, Mouw K, Szallasi Z, Melchior L, Dohn L, et al.
Sci Rep
. 2024 Nov;
14(1):27448.
PMID: 39523403
Background: Metastatic urothelial carcinoma (mUC) has a poor prognosis, despite recent therapeutic advancements. Prostaglandin Reductase 1 (PTGR1) is essential for activating acylfulvens, a promising class of drugs for treating a...
5.
Diossy M, Tisza V, Li H, Sahgal P, Zhou J, Sztupinszki Z, et al.
NPJ Precis Oncol
. 2024 Sep;
8(1):208.
PMID: 39294262
We analyzed genomic data from the prostate cancer of African- and European American men to identify differences contributing to racial disparity of outcome. We also performed FISH-based studies of Chromodomain...
6.
Anagho H, Mullari M, Prosz A, Buch-Larsen S, Cho H, Locard-Paulet M, et al.
Cell Rep
. 2024 Jul;
43(8):114603.
PMID: 39083379
No abstract available.
7.
Anagho H, Mullari M, Prosz A, Buch-Larsen S, Cho H, Locard-Paulet M, et al.
Cell Rep
. 2024 Jul;
43(7):114433.
PMID: 38985679
ADP-ribosylation (ADPr) signaling plays a crucial role in DNA damage response. Inhibitors against the main enzyme catalyzing ADPr after DNA damage, poly(ADP-ribose) polymerase 1 (PARP1), are used to treat patients...
8.
Stormoen D, Rohrberg K, Mouw K, Orum K, Szallasi Z, Rossing M, et al.
J Cancer Res Clin Oncol
. 2024 Jul;
150(7):339.
PMID: 38976041
Introduction: Urothelial tract cancer (UTC) ranks as the tenth most prevalent cancer and holds the seventh position in terms of mortality worldwide. Despite its prevalence and mortality ranking, there are...
9.
Kilim O, Olar A, Biricz A, Madaras L, Pollner P, Szallasi Z, et al.
medRxiv
. 2024 Jun;
PMID: 38883738
Patients with High-Grade Serous Ovarian Cancer (HGSOC) exhibit varied responses to treatment, with 20-30% showing resistance to platinum-based chemotherapy. While hematoxylin-eosin (H&E) pathological slides are used for routine diagnosis of...
10.
Prosz A, Sahgal P, Huffman B, Sztupinszki Z, Morris C, Chen D, et al.
NPJ Precis Oncol
. 2024 May;
8(1):98.
PMID: 38710943
No abstract available.